Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma
NCT00881387Phase 2Withdrawn
- Sponsor
- University of Miami
- Start
- Feb 2009
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in Hodgkin lymphoma (HL) (2 arms), sponsored by University of Miami. Primary endpoint: Response Rate (Complete Response, Unconfirmed Complete Response, Partial Response). Planned start Feb 2009; status: withdrawn.
02
Drugs
rituximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00881387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881387.